Adoption and implementation of medications in addiction treatment programs.
about
Assessment and treatment of mood disorders in the context of substance abuseA pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disordersEffects of an Organizational Linkage Intervention on Inter-Organizational Service Coordination Between Probation/Parole Agencies and Community Treatment ProvidersThe need for data-informed clinical supervision in substance use disorder treatment.Organizational implementation of evidence-based substance abuse treatment in racial and ethnic minority communitiesImpact of research network participation on the adoption of buprenorphine for substance abuse treatment.Development of a Multilevel Framework to Increase Use of Targeted Evidence-Based Practices in Addiction Treatment Clinics.Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependenceFrom research to the real world: buprenorphine in the decade of the Clinical Trials NetworkExtended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies.Improving treatment for opioid dependence: a perspective from the Ohio Valley node of the NIDA Clinical Trials Network.Counselor attitudes toward the use of naltrexone in substance abuse treatment: a multi-level modeling approachAdopting evidence-based medically assisted treatments in substance abuse treatment organizations: roles of leadership socialization and funding streamsA longitudinal examination of alcohol pharmacotherapy adoption in substance use disorder treatment programs: patterns of sustainability and discontinuationImplementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio.Adoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programsBarriers to use of pharmacotherapy for addiction disorders and how to overcome them.Persistence of addictive disorders in a first-offender driving while impaired populationThe role of expectation in the therapeutic outcomes of alcohol and drug addiction treatments.Timing of buprenorphine adoption by privately funded substance abuse treatment programs: the role of institutional and resource-based interorganizational linkages.Adapting the helpful responses questionnaire to assess communication skills involved in delivering contingency management: preliminary psychometrics.Physicians in the substance abuse treatment workforce: understanding their employment within publicly funded treatment organizations.Access to Addiction Pharmacotherapy in Private Health Plans.Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural CountiesBuprenorphine Prescribing Availability in a Sample of Ohio Specialty Treatment OrganizationsHow the paediatric workforce can address the opioid crisis.Perceptions of the state policy environment and adoption of medications in the treatment of substance use disorders.Correlates of Motivational Interviewing Use Among Substance Use Treatment Programs Serving American Indians/Alaska Natives.Longitudinal Examination of Medical Staff Utilization in Substance Use Disorder Treatment OrganizationsMedications development to treat alcohol dependence: a vision for the next decade.Improving Coordination of Addiction Health Services Organizations with Mental Health and Public Health Services.Financial factors and the implementation of medications for treating opioid use disorders.Implementation of Electronic Health Records and Entrepreneurial Strategic Orientation in Substance Use Disorder Treatment Organizations.Extended-Release Naltrexone: A Qualitative Analysis of Barriers to Routine UseThe Diffusion of Acamprosate for the Treatment of Alcohol Use Disorder: Results From a National Longitudinal StudyGrowth In Buprenorphine Waivers For Physicians Increased Potential Access To Opioid Agonist Treatment, 2002-11Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States.Naltrexone: Not Just for Opioids AnymoreUse of evidence-based treatments in substance abuse treatment programs serving American Indian and Alaska Native communities.Testing use of payers to facilitate evidence-based practice adoption: protocol for a cluster-randomized trial.
P2860
Q26798232-A1F08430-5F25-4EE3-A73D-076FD7712198Q27000732-19AF5B41-810B-4178-9516-1B15B925AB64Q28647492-5718BCC8-EEFC-409D-8D5C-54DD6064A932Q31159831-6D6E3F5A-E000-402A-84C3-623EEDDE23EBQ33707278-E585BC9B-B82E-46B0-8128-B63C4F3D9D88Q33776944-525369B8-FDD7-41D2-A2AE-FB101AF1B51DQ33777086-13264567-051F-4453-B52A-9B3AA4EF8FFBQ33783250-1AB9B893-66CE-48BC-856D-1AD8B3BB478DQ33783274-E4A158F7-F136-45FE-9347-E3FE2A2CF9B0Q33949899-B37E9562-7453-4680-876B-8AC64D83FEC6Q34404288-9F241F80-B9F9-4BFF-B378-67118ED53CD4Q34762315-790D86FE-6DB1-4091-BB58-CE71987078ADQ34806644-D40F101B-5989-429C-A300-0C4195512054Q35075932-08231E20-956C-46B9-A339-9AA2B3BCD7AFQ35400440-6CE6CB07-8932-4907-83E9-22E1DB64A8B9Q35447234-0E9D26CD-2E1A-4573-82C8-2FEABB1591E7Q35490468-2ED30BB1-317C-4077-985A-48C93E32B3AAQ35535658-1FE326A3-6187-4BD3-A0CC-BA962BBA9E6DQ35555236-888F39D1-FA0B-4E8A-A882-89F9D34ABBA3Q35577449-71931E9D-BA5E-49D1-BB1F-09B5C2DD0DE6Q35685241-D079D23B-0AA0-4BDF-BA0C-BF70E8D1FD6CQ35937004-B70B3A25-D5CE-433F-BAB5-7FDEECD77590Q36025907-106AA63F-31D2-4FF7-B58C-8E04C9EA9355Q36054084-02B9E049-2120-40AF-A4D9-0B426A9BC8CDQ36058075-2B55737B-8C8C-47B6-9F67-FEA9DD3F4F9EQ36145845-0EAB5253-B141-40EE-8969-FD67D050EC92Q36192673-BE48C1AC-A726-413C-A535-AA6952362151Q36290564-A5C8D78A-06CD-4601-820E-A1F59AE4E7C7Q36322546-9A9C6AEF-B2DB-4B50-8248-3C8644177AF9Q36357552-10888356-85A9-43DA-B4FD-A0C2E9CD0621Q36373003-3E55C26E-5753-4CE9-B385-58DE649621AFQ36381418-E4BD50AD-3CD8-4415-BFB8-839D68580E11Q36461870-9E29EB83-F7C1-4D92-B996-A539B0BF7E32Q36494796-E7557A0F-1C54-4131-9C9B-90971681233EQ36494890-BC1D87B2-3DFC-4750-9DC0-F4DA686E56F3Q36549928-3AEFE27F-01A9-4E1F-8AAD-513949DBC577Q36597560-9A8F2396-DC51-4CD7-AE15-14D2B7ECF962Q36660846-67593B17-D7EA-46F1-9A6A-938DC4EF7C65Q36757250-63E4BF88-1F81-4EFA-8F4A-C2486BC45D07Q36884980-999D15AC-5413-4585-B789-3E2435C665CF
P2860
Adoption and implementation of medications in addiction treatment programs.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Adoption and implementation of medications in addiction treatment programs.
@ast
Adoption and implementation of medications in addiction treatment programs.
@en
Adoption and implementation of medications in addiction treatment programs.
@nl
type
label
Adoption and implementation of medications in addiction treatment programs.
@ast
Adoption and implementation of medications in addiction treatment programs.
@en
Adoption and implementation of medications in addiction treatment programs.
@nl
prefLabel
Adoption and implementation of medications in addiction treatment programs.
@ast
Adoption and implementation of medications in addiction treatment programs.
@en
Adoption and implementation of medications in addiction treatment programs.
@nl
P2093
P2860
P1476
Adoption and implementation of medications in addiction treatment programs.
@en
P2093
Amanda J Abraham
Hannah K Knudsen
Paul M Roman
P2860
P356
10.1097/ADM.0B013E3181D41DDB
P577
2011-03-01T00:00:00Z